SMAD2 and gastric carcinoma: The ability of MFAP2 in activating TGF-β/SMAD2/3 pathway in gastric carcinoma has also been reported, and this activation accelerates the transformation of gastric carcinoma from an epithelial cell phenotype to a mesenchymal phenotype [11].